Founder and 100% involved in daily tasks. Master’s degree in Synthetic and Industrial Chemistry. He participated in the design and synthesis of the first MP compound.

He has previous entrepreneur experience (in 2010, founded an industrial start-up: Gomavial Solutions).

He is now leader of Miramoon Pharma. He is contracted fulltime on the project.

Expert with +25 years of experience in the pharmaceutical industry R&D and +5 as a Regulatory Affairs consultant to start-up and biotech companies.

Accompany and advices Miramoon with her expertise in EU and US regulations.

Provides the company with a strategic advisory, government and other public entities. Also helps Miramoon connecting to public financing and venture capital agents.

In terms of training for entrepreneurship is also a fundamental support.

Elena Canetti leads an expert team of consultants at Inveniam Group and  take care of all the activities related to market access, such as health economics analysis and market research.

Inveniam also provides support on public and private funding strategy and execution.

Founder. Expert in neuro-degenerative diseases and has permanent contact with patients affected by such conditions.

Provides medical and clinical expertise and, as a national authority in the area of neuroscience, facilitates access to national pharmaceutical companies and institutions. He is author or co-author of 225 reviewed articles, and 26 book chapters. 

Leads the economic-financial area. Develops and participates in the strategies and policies to optimize: Costing, Pricing, Cash and Investment Analysis with financing solutions, investment funds, grants and banking products.

Medicine and Surgery, specialized in Ophthalmology and retina (Hospital Universitario Donostia).

Published 22 articles and participated in 10 clinical trials and obtained several grants for clinical studies in Retinitis Pigmentosa.

Principal Investigator from 2010 to 2014 at CIMA of the University of Navarra, with funding from the Alzheimer’s Association of the USA.

Since 2015 principal investigator at the Biodonostia Institute.+15 years of experience in the study of neurodegeneration, published more than 40 publications (H=23), and supervised 2 PhDs and several master students.

Chemist with + 20 years’ experience in drug discovery and development, guided 15 novel drug classes into clinical phases and was appointed as inventor in over 200 patents.

Pharmacist (University of the Basque Country, Spain), MSc in Immunopharmacology (University of Strathclyde) and PhD in Neurology (King’s College London). She leads the Neuromuscular Research group at Biobizkaia Health Research Institute as an Ikerbasque Research Professor.

She has over 20 years’ experience in research in neuromuscular disorders, has participated in the development of several orphan drugs and chairs an international network of researchers in the field of nucleic acid therapeutics. She has authored many highly-cited scientific publications, serves in several Spanish and International grant review panels and has collaborated as an expert with the European Medicines Agency.